Neil Senzer

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.5K citations · Full text

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Denis Soulières, Neil Senzer, Everett E. Vokes et al. · Journal of Clinical Oncology · 2003 · 803 citations · Full text

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

Neil Senzer, Howard L. Kaufman, Thomas Amatruda et al. · Journal of Clinical Oncology · 2009 · 607 citations · Full text

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

John Nemunaitis, Robert O. Dillman, Paul Schwarzenberger et al. · Journal of Clinical Oncology · 2006 · 358 citations · Full text

Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients

John Nemunaitis, Casey Cunningham, Neil Senzer et al. · Cancer Gene Therapy · 2003 · 332 citations

E. Coli, Pilot Trial, Pathogen Detection +10